Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
Invivyd (NASDAQ: IVVD) has appointed Dr. Paul B. Bolno to its Board of Directors and Compensation Committee. Dr. Bolno, who currently serves as President and CEO of Wave Life Sciences, brings extensive experience in pipeline development and technological platforms for creating new medical products.
The appointment comes as Invivyd focuses on developing solutions for viral infectious diseases, particularly in the areas of COVID-19 prevention and treatment. Dr. Bolno also serves on the Board of ExpressionEdits and chairs the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator.
Invivyd (NASDAQ: IVVD) ha nominato il dottor Paul B. Bolno al suo Consiglio di Amministrazione e al Comitato di Retribuzione. Il dottor Bolno, attualmente presidente e CEO di Wave Life Sciences, vanta una vasta esperienza nello sviluppo di pipeline e nelle piattaforme tecnologiche per creare nuovi prodotti medici.
La nomina avviene mentre Invivyd si concentra sullo sviluppo di soluzioni per malattie virali infettive, in particolare per la prevenzione e il trattamento della COVID-19. Il dottor Bolno è anche membro del Consiglio di ExpressionEdits e presiede il Gruppo di Consulenza Scientifica per il Nucleic Acid Therapy Accelerator.
Invivyd (NASDAQ: IVVD) ha designado al Dr. Paul B. Bolno para su Junta Directiva y para el Comité de Compensación. El Dr. Bolno, actual Presidente y CEO de Wave Life Sciences, aporta amplia experiencia en desarrollo de pipelines y plataformas tecnológicas para crear nuevos productos médicos.
El nombramiento coincide con el enfoque de Invivyd en soluciones para enfermedades virales infecciosas, especialmente en la prevención y el tratamiento de la COVID-19. El Dr. Bolno también forma parte de la Junta de ExpressionEdits y preside el Grupo Asesor Científico del Nucleic Acid Therapy Accelerator.
Invivyd (NASDAQ: IVVD)는 이사회 및 보상위원회에 폴 보노 박사를 임명했습니다. 현재 Wave Life Sciences의 사장 겸 최고경영자로 재직 중인 보노 박사는 파이프라인 개발과 새로운 의약품 생성을 위한 기술 플랫폼에 대한 방대한 경험을 보유하고 있습니다.
이번 임명은 Invivyd가 COVID-19 예방 및 치료를 포함한 바이러스성 전염병 솔루션 개발에 집중하는 가운데 이뤄졌습니다. 보노 박사는 ExpressionEdits의 이사회에서도 활동하며 Nucleic Acid Therapy Accelerator의 과학자 자문위원회를 이끕니다.
Invivyd (NASDAQ: IVVD) a nommé le Dr Paul B. Bolno au conseil d’administration et au comité de rémunération. Le Dr Bolno, actuellement président et PDG de Wave Life Sciences, apporte une vaste expérience du développement de pipelines et des plateformes technologiques pour créer de nouveaux produits médicaux.
Cette nomination s’inscrit dans le cadre de l’objectif d’Invivyd de développer des solutions pour les maladies virales infectieuses, en particulier la prévention et le traitement de la COVID-19. Le Dr Bolno siège également au conseil de ExpressionEdits et préside le groupe consultatif scientifique du Nucleic Acid Therapy Accelerator.
Invivyd (NASDAQ: IVVD) hat Dr. Paul B. Bolno in den Vorstand und den Vergütungsausschuss berufen. Dr. Bolno ist derzeit Präsident und CEO von Wave Life Sciences und bringt umfassende Erfahrung in der Pipeline-Entwicklung und in technologischen Plattformen mit, um neue medizinische Produkte zu schaffen.
Die Berufung erfolgt, während Invivyd sich darauf konzentriert, Lösungen für virale Infektionskrankheiten zu entwickeln, insbesondere zur Prävention und Behandlung von COVID-19. Dr. Bolno ist zudem Vorstandsmitglied von ExpressionEdits und leitet die Scientific Advisory Group des Nucleic Acid Therapy Accelerator.
Invivyd (NASDAQ: IVVD) عينت الدكتور بول بي بولنو في مجلس إدارتها ولجنة التعويضات. الدكتور بولنو، الذي يشغل حالياً منصب الرئيس التنفيذي لشركة Wave Life Sciences، يجلب خبرة واسعة في تطوير خطوط الأنابيب والمنصات التكنولوجية لإنشاء منتجات طبية جديدة.
يأتي التعيين في وقت تركز فيه Invivyd على تطوير حلول للأمراض الفيروسية المعدية، خاصة في مجالات الوقاية من COVID-19 وعلاجه. الدكتور بولنو يشغل أيضاً عضوية مجلس ExpressionEdits ويرأس المجموعة الاستشارية العلمية لـ Nucleic Acid Therapy Accelerator.
Invivyd（纳斯达克代码：IVVD） 已任命 Paul B. Bolno 博士 为董事会成员及薪酬委员会成员。Bolno 博士现任 Wave Life Sciences 的总裁兼首席执行官，拥有丰富的管线开发经验及用于开发新医疗产品的技术平台经验。
此次任命正值 Invivyd 致力于开发针对病毒性传染病的解决方案，特别是在 COVID-19 的预防和治疗领域。Bolno 博士还任 ExpressionEdits 董事会成员，并担任核酸治疗加速器（Nucleic Acid Therapy Accelerator）科学顾问组主席。
- None.
- None.
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013.
“We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming ill from major viral infectious diseases,” said Marc Elia, Chairman of the Board of Invivyd. “Dr. Bolno’s extensive experience in leading Wave Life Sciences through rapid pipeline development will be a boon to Invivyd as we seek to advance our pipeline so that we may help as many people as possible stay healthy from targeted infectious diseases.”
Dr. Bolno brings diverse experience utilizing technological platforms to create new products and medications. In addition to his role at Wave Life Sciences, he serves on the Board of Directors of ExpressionEdits and is the Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator.
“I am honored to join the Board of Invivyd, as we share a sense of urgency to keep Americans healthy via our deep commitment to scientific excellence,” said Paul B. Bolno, M.D. “Invivyd’s unique capabilities and ability to drive meaningful innovation in viral infectious disease can add high quality options in prevention and treatment of acute COVID, and potentially treatment of Long COVID, all of which are sorely needed in modern American healthcare.”
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “could,” “expects,” “estimates,” “intends,” “potential,” “predicts” “projects,” and “future” or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company’s focus on helping large populations avoid becoming ill from major viral infectious diseases and its efforts to advance its pipeline to help as many people as possible stay healthy from targeted infectious diseases; the anticipated contributions of the company’s new director the potential of Invivyd to drive meaningful innovation in viral infectious disease and add high quality options in prevention and treatment of acute COVID, and potentially treatment of Long COVID; the company’s devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company’s forward-looking statements and you should not place undue reliance on the company’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress and results of the company’s discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data; how long the EUA granted by the U.S. FDA for a mAb in the company’s pipeline will remain in effect and whether the EUA is revised or revoked by the U.S. FDA; whether the company’s product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; changes in the regulatory environment; the outcome of the company’s engagement with regulators; changes in expected or existing competition; the company’s reliance on third parties; the complexities of manufacturing mAb therapies; macroeconomic and political uncertainties; the company’s ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the company’s Annual Report on Form 10-K for the year ended December 31, 2024, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each as filed with the Securities and Exchange Commission (SEC), and in the company’s other filings with the SEC, and in its future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Contacts:
Media Relations
(781) 208-1747
media@invivyd.com
Investor Relations
(781) 208-1747
investors@invivyd.com
FAQ
Who is Paul B. Bolno and what is his new role at Invivyd (IVVD)?
What experience does Dr. Bolno bring to Invivyd's (IVVD) Board?
What are Invivyd's (IVVD) current focus areas in infectious diseases?
When did Invivyd (IVVD) announce the appointment of Dr. Paul Bolno?
